- Zilurgisertib reduced total HO lesion volume and improved clinician-assessed joint mobility; no zilurgisertib-treated patients developed new HO lesions

- Mirum plans to submit an sNDA in H1 2027 to expand the ATEBRIOZ indication to pediatric patients aged 6 to <12 years

- Safety and efficacy findings consistent with PROGRESS Cohort 1; no new safety signals

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.